Please provide your email address to receive an email when new articles are posted on . Javaheri reported an average treatment interval of 70 days in treatment-naive patients with DME or wet AMD.
High-dose aflibercept offers extended dosing intervals for DME and wet AMD, with sustained visual and anatomical improvements. The PULSAR and PHOTON trials showed efficacy in maintaining vision gains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback